Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.